Safety and Efficacy of Armodafinil for Fatigue Associated With Taxanes Alone or in Combination With Other Agents
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Armodafinil Treatment (150 mg/Day) for Patients With Fatigue Associated With Taxane Chemotherapy Alone or in Combination With Other Agents
Sponsor: Cephalon
Listed as NCT00825227, this PHASE2 trial focuses on Chemotherapy Side Effects and Fatigue and remains terminated or withdrawn. Sponsored by Cephalon, it has been updated 12 times since 2008, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Jan 2022 — Dec 2022 [monthly]
Terminated PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Dec 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Dec 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cephalon
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abingdon, United States, Atlanta, United States, Augusta, United States, Bethesda, United States, Billings, United States, Burbank, United States, Cedar Rapids, United States, Charleston, United States, Danville, United States, Fountain Valley, United States and 18 more location s